Let's Talk Quality: The Newsletter
Welcome to the latest edition of Let's Talk Quality: The Newsletter!
Message from Hemish
September was a busy month for our consultant network!
It's been well documented how tough this year has been for pharma and biotech. Poor clinical data and a more conservative funding environment has driven a huge increase in lay-off's in comparison to previous years.
Nonetheless, the market for short term resource remains strong across the US. Last month we placed consultants in projects involving QMS assessments, clinical quality audits, and new GMP facility & laboratory build outs.
On the permanent side, things are definitely picking up, and it 'feels' like we're over the worst of the lay-off's that have impacted the industry this year.
Recruitment processes are moving faster, but there are still director and VP level roles out there that are seeing hundreds of applicants - making it hard for in-house TA teams, leading to slower processes and potentially several well qualified candidates being missed out on.
As we move into Q4, this is traditionally a busy period in biotech. Have a look at our live roles below if you are interested in new opportunities, and please get in touch with us if we can help you.
I hope you have a great October, and you're feeling optimistic about the last quarter of the year!
Hemish
Founder, Rx Group
Let's Talk Quality: The Podcast
We've now approaching our 10th episode of Let's Talk Quality: The Podcast???
A huge thank you to our guest so far. If you haven't had the chance to listen, then please go onto Apple or Spotify, and hit subscribe!
You can listen to each episode by clicking here.
领英推荐
Here's a clip from our latest episode with Peggy Owens .
Pharma and Biotech Funding Landscape
Here’s how the US and European sectors performed last month, specifically within VC and private equity.
In the US, there were 21 deals throughout September, for a total deal value of $1,300m USD. In Europe, there were 13 deals in September, for a total of $507m USD total value.
US performance was overall pretty consistent with August (20 deals for 1.3m USD), but in Europe, deal value and volume doubled last month.
Top 3 deals:
Generate:Biomedicines - $273m US - Series C
Mariana Oncology - $175m US - Series B
Avalyn Pharma - $175m US - Series C
In the US, it wasn't the huge increase we were hoping for, however a huge spike for Europe with the UK and France coming out strongly. Let's hope for another strong month for funding in October.
Live Permanent Jobs
We're working on some exciting positions with companies across cell and gene therapy, mRNA and combination products.